Introduction
The c-MYC proto-oncogene codes for a nuclear phosphoprotein ubiquitously expressed in somatic cells (Eisenman, 2001; Grandori et al., 2000) . Alterations of the c-MYC locus, caused by chromosomal translocation, amplification, retroviral insertion, or retroviral transduction, deregulate c-MYC expression and contribute to tumorigenesis in different species (Bouchard et al., 1998; Grandori et al., 2000; Nesbit et al., 1999) . The c-MYC protein contains domains which are typical of several types of transcription factors, including a carboxy-terminal basic, helix -loop -helix and leucine -zipper (b-HLH-LZ) domain which can mediate the formation of oligomeric complexes capable of specific DNA binding (Landschulz et al., 1988) and an amino-terminal domain necessary for transcriptional transactivation (Kato et al., 1990) . A second b-HLH-LZ protein, MAX, can specifically associate with c-MYC in vitro to form heterodimeric complexes (Blackwood and Eisenman, 1991) capable of binding DNA at a specific site (E-box) and activate transcription of target genes (Blackwell et al., 1993; Kretzner et al., 1992) . MYC/ MAX heterodimers regulate transcription by recruiting protein complexes that can regulate histone acetylation and modify chromatin structure (Bouchard et al., 2001; Eisenman, 2001; Frank et al., 2001 ).
The precise function of the c-MYC protein, and in particular the mechanism by which it promotes cell proliferation in normal and neoplastic cells, is not known. Using a variety of approaches, including genome-wide gene expression profiling, various c-MYC target genes have been identified. These genes include both direct targets, i.e. gene whose transcription is regulated by direct binding of c-MYC to their promoter region, as well as indirect targets, i.e. genes whose expression changes as a consequence of the gene expression program directly regulated by c-MYC. Target genes have been shown to be involved in heterogeneous functions, including cell cycle control, DNA synthesis, iron metabolism, protein synthesis, apoptosis, cell adhesion and telomere maintenance (Dang, 1999; Grandori et al., 2000) . In Drosophila as well as in mammalian cells, c-MYC has been shown to promote cell growth (Iritani and Eisenman, 1999; Johnston et al., 1999) , although it has been recently reported that c-MYC may control organ and body size by regulating cell cycle entrance rather than cell size (Trumpp et al., 2001) .
A better definition of the precise role of c-MYC depends upon the identification of the genes that are directly targeted by its transcriptional regulation function. Here we report that c-MYC regulates the expression of the gene encoding the catalytic subunit beta of protein kinase A (PKA-Cb), a key effector of cAMP induced signal transduction. PKA normally exists in the cytoplasm as an inactive tetrameric holoenzyme which is dissociated into two free catalytic and two regulatory subunits when cAMP is generated upon binding of hormones to their receptors and activation of adenylate cyclase (Daniel et al., 1998; Taylor et al., 1990) . The PKA free active catalytic subunits (Ca, Cb or Cg) (Skalhegg et al., 1992) phosphorylate serine and threonine residues on specific substrate proteins which include transcription factors involved in cell activation and proliferation (Daniel et al., 1998; Dhanasekaran et al., 1995; Montminy, 1997) . Our results indicate that, by up-regulating the expression of the PKA-Cb gene, c-MYC induces PKA activity, thus leading to the activation of the c-AMP signal transduction pathway in the absence of c-AMP dependent ligands.
Results

Expression of c-MYC is associated with increased PKA-Cb gene expression in vitro and in vivo
To isolate c-MYC target genes, we exploited a previously described B cell line (EREB.TCMyc) in which proliferation and c-MYC expression could be independently controlled (Wu et al., 1999a,b) . Since in these cells the EBV EBNA-2 gene (which induces B cell immortalization) is expressed as a chimeric fusion with the hormone binding domain of the estrogen receptor (Kempkes et al., 1995) , estrogen (E2) removal leads to growth arrest (G0/G1) associated with complete downregulation of endogenous c-MYC expression (see Figure 1a , +TC/7E2 lanes). Since these cells have also been transfected with a tetracycline (TC)-repressed c-MYC vector (Wu et al., 1999b) , exogenous c-MYC expression can then be induced by TC withdrawal. Induction of c-MYC is not sufficient to cause cell cycle entrance and the cells remain quiescent and viable for several days. Using a cDNA probe generated from RNAs harvested from cells in quiescent status (+TC/ 7E2) or from cells overexpressing exogenous c-MYC (7TC/7E2), we screened a cDNA micro-array filter containing cDNA clones corresponding to 5000 genes (Research Genetics). Among numerous genes displaying differential expression in c-MYC expressing cells (not shown), we focused on the PKA-Cb gene, whose expression appeared significantly induced in 7TC/ 7E2 EREB.TCMyc cells. To validate the result obtained from the screening of the microarray filter, we analysed PKA-Cb expression upon c-MYC induction in the same cells by Northern blot hybridization analysis. The results showed that withdrawal of E2 and TC (causing induction of exogenous c-MYC) was associated with a threefold increase (2.5 -4.8-fold in different experiments) in the expression of PKA-Cb RNA (Figure 1a ). This result also indicates that c-MYC can induce PKA-Cb expression in the absence of cell proliferation.
To further confirm the relationship between c-MYC and the expression of PKA-Cb, we used a human EBVimmortalized B cell line (CB33) engineered to express high levels of either c-MYC/MAX (CBMyc.Max) or MAX/MAX (CBMax) complexes, representing the two extreme regulatory situations of high and very low c-MYC function, respectively. The phenotype of these cells was previously characterized and shown to be consistent with their differential c-MYC expression levels since CBMyc.Max cells display a short doubling time, have clonogenic properties in vitro and cause tumors in vivo, while CBMax cells proliferate very slowly and lack any transformation-related phenotype (Gu et al., 1993) . Northern blot analysis of these cell lines showed that the expression of PKA-Cb RNA was significantly increased (*10-fold) in CBMyc.Max cells when compared to control transfected cells (CB control) or CBMax cells (Figure 1b, left panel) . Furthermore, PKA-Cb RNA levels were decreased in U937 cells induced to terminal monocytic differentiation by phorbol 12-myristate 13-acetate (TPA) treatment, a process that requires down-regulation of c-MYC expression (Larsson et al., 1988) (Figure 1b To verify the relationship between c-MYC deregulation and PKA-Cb gene expression in vivo, we performed Western blot analysis of B cells purified from the spleen of mice expressing a transgenic l-MYC construct driven by B cell specific transcriptional regulatory elements (Kovalchuk et al., 2000) . Figure 1d shows that CD19+ cells from two transgenic l-MYC mice, but not those from wild-type littermate controls, overexpress both c-MYC and PKA-Cb. Taken together, these results indicate that increased c-MYC expression is associated with increased PKA-Cb RNA and protein levels in multiple cell types and in different physiological conditions both in vitro and in vivo.
Induction of PKA-Cb gene expression by c-MYC in the absence of de novo protein synthesis
To investigate whether c-MYC-mediated upregulation of PKA-Cb gene expression was direct, we first studied Figure 1 Relationship between c-MYC and PKA-Cb RNA and protein expression in different cell types. (a) Activation of PKA-Cb RNA expression by c-MYC in the absence of cell proliferation. Northern blot analysis of RNA from EREB.TCMyc cells upon estrogen (E2) withdrawal and c-MYC activation by tetracycline (TC) withdrawal. The same blot was sequentially hybridized with an exon-3 genomic c-MYC probe (which detects both endogenous and exogenous (pTCMyc plasmid) c-MYC RNA species), an exon-1 c-MYC probe (which detects only the endogenous c-MYC RNA since exon-1 sequences are not present in the transfected pTCMyc plasmid) and a b-actin cDNA probe (control for RNA loading). Twenty-four hours after E2 withdrawal, cells were examined for proliferation by flow-cytometric analysis of DNA content and found to be arrested at G0/G1 as previously described (Wu et al., 1999b) ; no change in cell cycle activity was detectable after induction of c-MYC by TC withdrawal. ). This protein can be rapidly activated by 4-hydroxytamoxifen (TM), but not by E2 (Littlewood et al., 1995; Sasson, 1991) ; in turn, TM can activate MYCER TM , but not ER-EBNA-2, allowing for the selective activation of preexisting MYCER TM in resting B cells. By this approach, and by simultaneous treatment with the protein synthesis inhibitor cyclohexamide (CX), we examined whether PKA-Cb gene expression could be regulated upon activation of pre-existing MYCERTM in the absence of de novo protein synthesis. Figure 2a shows that TM treatment led to a significant (ninefold) and rapid (detectable after 1 h) increase in PKA-Cb mRNA levels. This induction is partially reduced (to fourfold), but reproducibly persists, upon co-treatment with CX (CX+TM), indicating that induction of PKACb gene expression involves a mechanism that is, at least in part, independent of de novo protein synthesis. The difference in PKA-Cb induction between TM and TM+CX treatment is explained by the observation that TM treatment also leads to a modest CX-sensitive induction of c-MYC and PKA expression (results obtained in TM-treated EREB control cells; not shown). The rapid kinetics of c-MYC-induced upregulation and its independence of cellular proliferation and de novo protein synthesis are consistent with a direct effect of c-MYC activation on PKA-Cb gene expression. To conclusively demonstrate that the upregulation of PKA-Cb gene expression by c-MYC is direct, we first investigated whether the PKA-Cb promoter region contains sequences which could mediate c-MYCinduced activation (Blackwell et al., 1993; Kretzner et al., 1992) . The genomic organization of the 5' flanking region of the human PKA-Cb gene is schematically reported in Figure 3a . This information was derived by sequencing two overlapping genomic clones (pBSBamHI (5.5 kb) and pBS-HdIII (6.6 kb)) that include 5.2 kb of sequence upstream of the PKA-Cb transcription start site, the exon 1 (93 bp) and 2.7 kb of intron 1. Sequence analysis revealed the presence of two 'noncanonical' E-box sites (CACGCG) in the 5' flanking region and one E-box site (CACGTG) located within the first intron.
We then tested whether a c-MYC expression vector (pMT2T-Myc) could induce the transcriptional activation of a reporter construct (CbLuc3000; Figure 3b ) containing a 3000 bp segment of the PKA-Cb 5' region linked to the coding domain of the luciferase gene (Luc) (Nordeen, 1988) in co-transfection assays in Ntera2 cells. Figure 3b shows that c-MYC was able to induce the expression of the CbLuc3000 construct at levels (4 -6-fold) comparable to those observed for other c-MYC target genes in similar assays (Dang, 1999; Gu et al., 1993; Wu et al., 1999a,b) , indicating that the promoter region of the PKA-Cb gene can be transcriptionally activated by c-MYC. Conversely, two deletion mutants, lacking the c-MYC transactivation (pMT2TMyc(D7 -91)) or the heterodimerization domain (pMT2TMyc(D371 -412)) (Stone et al., 1987) , were unable to induce the expression of the CbLuc3000 reporter, indicating that c-MYC-mediated activation of PKA-Cb transcription required both the transactivation domain and heterodimerization with MAX, as expected for physiological c-MYC function. These results indicate that c-MYC can induce activation of the PKA-Cb gene transcription presumably by binding to sites present within its 5' and/or intron 1 regions.
In order to demonstrate that c-MYC can bind the PKA-Cb promoter region in vivo and to localize the target sequences, we investigated whether these sequences could be found in chromatin immunoprecipitated by anti-c-MYC and/or anti-MAX antibodies in CBMyc.Max cells or in EREB cells cultured in the absence of estrogen (EREB, 7E2) and therefore lacking c-MYC (see Figure 1a) . After crosslinking of protein to DNA, chromatin was immunoprecipitated with a-MYC and/or a-MAX antibodies, or with a species and isotype-matched control antibody (aOsteoprotegirin). The presence of c-MYC sequences within the immunoprecipitates was analysed by PCR using three different sets of primers that amplify the two regions containing the 'non canonical' (A region) and 'canonical' (B region) c-MYC binding sites and downstream coding sequences as a negative control (C region) (Figure 4a ). The results (Figure 4b ) show that . PCR reactions were performed on both 2% input chromatin (total input) and immunoprecipitated products. Genomic DNA was used as a positive control for the PCR end, Rat1A cells were stably transfected with a PKACb expression vector and then tested for their ability to produce colonies in soft agar, a trait of malignant transformation. All of the nine tested Rat1A clones constitutively expressing PKA-Cb acquired clonogenicity at levels comparable to those displayed by c-MYCtransformed Rat1A cells, while none of nine controltransfected clones was above background (see Figure  6a for representative results). The clonogenic activity acquired by PKA-Cb transfected clones roughly correlated with the amount of PKA-Cb detectable by Western blot analysis, although clonal variations were observed (see Figure 6b for representative results). Notably, treatment with H-89 (a PKA inhibitor) caused a significant decrease in clonogenicity in both PKA-Cb and c-MYC-transformed cells (Figure 6a) . Nonetheless, in contrast with c-MYC, overexpression of PKACb was not associated with the induction of apoptosis upon serum-deprivation (data not shown), consistent with the observation that distinct target genes are involved in the proliferative and apoptotic responses to c-MYC (James and Eisenman, 2002) . Overall, these data are consistent with a role of PKACb in c-MYC-induced transformation in vitro.
Discussion
The results presented in this study identify the PKACb gene as a direct target for c-MYC transcriptional regulation. While many c-MYC targets have been recently identified (Dang, 1999; Grandori et al., 2000) , PKA-Cb represents one of the relatively limited number of genes that are proven to be direct as opposed to secondary targets for c-MYC transcriptional activation. This conclusion is supported by the fact that PKA-Cb transcription can be induced by preexisting c-MYC in the absence of de novo protein synthesis (Figure 2) and, more directly, by the demonstration that c-MYC directly binds to the PKA-Cb promoter region in vivo (Figure 4) . Although not precisely mapped by our results, the PKA-Cb sequences bound by c-MYC include the 160 bp region that contain two 'non-canonical' c-MYC binding sites, both flanked by sequences considered optimal for c-MYC binding and similar to those found in the c-MYC binding sites of the ODC and TERT genes (Bello-Fernandez et al., 1993; Wu et al., 1999a) . A canonical E-box located within intron 1 showed reproducibly weaker binding in the ChIP assay and has less favorable flanking sequences. It is conceivable that the 5' flanking region may represent the primary target while the intron 1 site may become functional in the presence of high levels of c-MYC/MAX heterodimers. Overall, while the number and the relative affinity of functional c-MYC binding sites remain to be determined, our results indicate that c-MYC binds to the 5' promoter region of the PKA-Cb gene in vivo.
Regardless of the precise site of binding, c-MYCmediated activation of PKA-Cb is relevant in that it induces PKA, a key effector of the signal transduction pathway initiated by the binding of hormones to their receptors and mediated by cAMP. Following receptor activation, cAMP dissociates the PKA complex generating free active catalytic subunits (Ca, Cb or Cg) (Skalhegg and Tasken, 2000) capable of phosphorylation and activation of various transcription factors (CREB, CREM, NF-kB, and AP1) (Daniel et al., 1998; Feuerstein et al., 1996; Montminy, 1997; Pursiheimo et al., 2000; Taylor et al., 1990; Zhong et al., 1997) controlling pleiotropic functions, including cell activation and DNA synthesis. The findings presented in this study suggest that, by activating PKA-Cb expression, c-MYC may cause a stoichiometric excess of free Cb units, thus leading to PKA activation through a cAMP-independent mechanism.
By directly activating PKA-Cb, c-MYC can induce the c-AMP signal transduction pathway in the absence of c-AMP dependent ligands. This hypothesis is consistent with the observations that Drosophila (Jiang and Struhl, 1995) and mammalian cells (Qi et al., 1996; Zhong et al., 1997 ) display a basal level of ligandindependent PKA activity and that this activity is increased in proliferating cells (when c-MYC is also expressed) (Figure 5 ). c-AMP-mediated PKA activation has been shown to have cell-type specific effects on cell growth, including mitogenic effects in some cell types (Zachary et al., 1990) and anti-proliferative effects in numerous others (Chen and Iyengar, 1994) . These opposite effects have been explained by the celltype specific effects of cAMP in activating or inhibiting ERK, a critical regulator of cell growth (Burgering et al., 1994; Schmitt and Stork, 2001; Vossler et al., 1997) . The observation that constitutive expression of PKACb induces transformation of Rat1a cells (Figure 6a ) is consistent with a positive role of PKA on proliferation in these cells; however, it cannot be excluded that the excess of free PKA-Cb subunits may generate signals different from those generated by c-AMP-induced dissociation of PKA. Induction of PKA as a positive Figure 5 c-MYC induces increased PKA activity. EREB.MycER TM cells were withdrawn from estrogen (E2) for 4 days and stimulated with 4-hydroxytamoxifen (TM) or forskolin (FSK) for 6 h; PKA activity was assayed using the SignaTECT cAMPDependent Protein Kinase Assay kit (Promega). The results are shown as percentages of PKA activity in resting (E2-) vs proliferating (E2+) cells regulator of cell activation and DNA synthesis (Daniel et al., 1998; Montminy, 1997) would be consistent with a role of c-MYC as a metabolic facilitator of cell growth and proliferation (Iritani and Eisenman, 1999; Johnston et al., 1999; Trumpp et al., 2001) . Endogenous, ligand-independent activation of a signaling pathway represents a novel function for c-MYC, which, by this means, may contribute to growth and proliferation by rendering the cell relatively independent of specific extracellular signals.
These findings also have implications for c-MYCassociated tumorigenesis. The results shown in Figure  6 suggest that PKA activation is a crucial component of the program by which constitutive c-MYC expression contributes to cell transformation. Notably, since c-MYC-induced transformation can be reverted by pharmacological inhibition of PKA, these findings suggest a therapeutic strategy for the treatment of the multiple tumor types that express deregulated c-MYC. 
Materials and methods
Cell lines and plasmids
The lymphoblastoid cell lines, EREB.TCMyc and EREB.-MycER TM cells were previously described (Wu et al., 1999b) . The pHeBO-CMV-Cb plasmid was constructed by RT -PCR amplification of a *1.1 kb fragment of the human PKA-Cb cDNA from EREB.TCMyc mRNA. The primers used to generate this fragment are: 5'-CCCCTGCTAGCCATCGC-CCCAGACATGGGGAACG-3'; 3'-AACAAGGGCGGCC-GCAGCTCTACCTTATCTCTCA-5'. This fragment was cloned into pGEM-T vector (Promega) to generate pGEMCb and analysed by sequencing. The cDNA (+33 to +1170) containing the full coding region of the PKA-Cb gene was subsequently cloned into the NheI -NotI sites of pHeBO-CMV vector to make the pHeBO-CMV-Cb expression vector.
cDNA microarray filter screening
One mg of poly(A) RNAs from EREB.TCMyc cells in either quiescent status (+TC/7E2) or in c-MYC overexpressing status (7TC/7E2) was converted into cDNA and labeled according to the Research Genetics protocol. The same cDNA microarray representing about 5000 clones was sequentially hybridized to these two different probes and washed following the manufacturer's instructions. The signals from two different hybridizations were compared and analysed using the Research Genetics software.
Isolation of mouse splenic B cells
B cells were isolated from mouse spleen by magnetic cell separation using the MidiMACS system (Miltenyi Biotech). Following tissue disgregation, cells were incubated with CD19-Microbeads (Miltenyi Biotech) and magnetically labeled cells were isolated passing through a LS-column (Miltenyi Biotech). The flow-through samples were collected as CD197 fractions. The enrichment for CD19+ cells (85 -89%) in the eluted fractions was verified by FACS analysis. CD197 fraction showed a minor contamination from CD19+ cells (3 -7%).
Northern blot analysis
Fifteen mg of RNA was used in each lane of the Northern blots. In EREB.MycER TM Northern blots, 7 -10 mg of poly(A) RNA were used. The human PKA-Cb probe was generated by NheI-NotI digestion of the pHeBO-CMV-Cb plasmid mentioned above. Vimentin probe was kindly provided by R Liem. c-MYC exon 3 and exon 1 probes were obtained from the pMC41RC and pMC41ER plasmids, respectively (Dalla-Favera et al., 1982) . The SV40 poly(A) tail probe and human b-actin probe were previously described (Wu et al., 1999b) .
Western blot analysis
Forty mg of cellular extracts (CB control, CBMyc.Max, CBMax, Figure 1c ; RatMyc, RatCMV, RatCMV-PKA-Cb, Figure 6b ) and 4 mg of control extracts (293T control, 293T-PKA-Cb) were loaded onto a 10% SDS -PAGE gel and transferred to a nitrocellulose filter. For the Western blot analysis of CD19 positive and negative fractions from l-MYC transgenic mice (Figure 1d ), 90 mg of total extracts were loaded on 10% SDS -PAGE gel. The filters were probed with a polyclonal anti-PKA-Cb antibody (C-20; Santa Cruz Biotechnology), monoclonal anti-human c-MYC (9E10; Santa Cruz Biotechnology) and a monoclonal anti-b-actin antibody (AC-74; Amersham Pharmacia Biotech) as a control for protein loading. Signals were revealed using a chemiluminescence kit (ECL, Amersham Pharmacia Biotech).
PKA-Cb promoter region, generation of PKA-Cb-driven reporter constructs and transient transfection/reporter gene assays A human genomic library (a generous gift of B Tycko) generated from sperm DNA in lambda DASH II (Stratagene) was screened using as a probe a DNA fragment encompassing the first 200 nucleotides of the PKA-Cb cDNA sequence (Shuntoh et al., 1992) . Inserts of positive, purified plaques were subcloned and characterized by restriction enzyme digestion, Southern blot analysis and nucleotide sequencing. To generate the CbLuc3000 reporter construct, a 3.0 kb fragment of the PKA-Cb promoter region containing 686 bp upstream of the ATG translation initiation codon, the first exon, and 2.25 kb of the intron 1 was subcloned into the HindIII site of the pXP2 promoterless luciferase vector. The ATG translation initiation codon of PKA-Cb (located within exon 1) was changed to GTG by site directed mutagenesis to ensure that translation initiates from the luciferase coding sequences. This reporter construct was co-transfected into Ntera2 cells with 1.2 pmol of either a c-MYC wild type expression vector (pMT2TMyc) or c-MYC deletion mutants (pMT2TMyc(D7 -91) and pMT2TMyc(D371 -412)) or a control vector (pMT2T) into Ntera2 cells by the CaPO 4 precipitation method. A plasmid expressing the bacterial b-galactosidase gene (pCMVbgal, 0.5 mg) was also co-transfected in each experiment to serve as an internal control for transfection efficiency. Two days after transfection, cells were harvested and their luciferase activities were assayed.
Chromatin immunoprecipitation assay
A detailed protocol for formaldehyde crosslinking and chromatin immunoprecipitation has been published (Frank et al., 2001) . Rabbit polyclonal antibodies (2 mg) specific for c-MYC (N-262, Santa Cruz Biotechnology, sc-764), for MAX Santa Cruz Biotechnology, or for OPG (osteoprotegerin) (H-249, Santa Cruz Biotechnology, sc-11383) were used to precipitate chromatin from 2.5610 7 CBMyc.Max or EREB resting (7E2) cells. Immunecomplexes were recovered by adding 30 ml of blocked salmon sperm DNA/Protein A agarose beads (UpState Biotechnology). Immunoprecipitated samples and no antibody controls were resuspended in 30 ml of TE 1X; total input samples (representing 2% of the total input chromatin) were resuspended in 60 ml of TE 1X. Specific E-box sequences on PKA-Cb 5'-region and intron 1 were detected by PCR amplification using 3 ml of the immunoprecipitated DNA samples as template and two different specific primers pairs: (1) 5'-GACCCAGAGGCCACCTTG-3' and 5'-GAGGTGGCGTGGACCGCTT-3' for the generation of A fragment (300 bp); (2) 5'-GGAAACTGAAGGTC-ATTATAG-3' and 5'-TACACAGAACATTTAGGTACG-3' for the generation of B fragment (230 bp). One primer set (5'-AGGCTCTGGAGATACCAGCA-3' and 5'-GCTTAG-CGGTGCCTTG-TTAC-3') amplifying a region of the PKA-Cb exon 9 (C fragment, 285 bp) was also used as negative control. Following 32 to 35 cycles of amplifica-tion, PCR products were run on 2% agarose gels and analysed by ethidium bromide staining.
PKA assay
Cell pellets were washed once in 16PBS, extracted by extraction buffer (40 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 1 mM ZnCl, 1 mM PMSF, 0.2% NP-40, and protease inhibitors (CalBiochem)) and then sonicated. After spinning in a microfuge for 15 min, the supernatant was collected, the protein concentration was determined by BioRad Protein Assay (Bio-Rad Laboratories) and 20 mg of cell extracts were used for each assay. Protein kinase catalytic subunit assays were performed using the SignaTECT cAMPDependent Protein Kinase Assay kit (Promega).
Soft agar colony assay
Rat1A cells were stably transfected with the pHeBO-CMVCb or pHeBOCMV expression vectors and the resulting clones were plated at three different cell densities (2.5610 3 , 5610 3 , 10 4 ) using standard assay conditions as previously described (Gu et al., 1993) . The PKA inhibitor H-89 (Calbiochem) was added to the culture medium at a final concentration of 10 mM.
